Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=16953 TRMS is a biotech firm engaged in the development of theraputic agents that block viral infection by inhibiting viral fusion with host cells. Their lead product candidate (T-20), inhibits fusion of HIV-1 with host cells. T-20 has been tested in a Phase I/II trial as a MONOTHERAPY for HIV infected patients in the US. Besides being safe & well-tolerated, the 4 patients in the trial who received the higest dose experienced a reduction in viral load to below detectable levels with an assay sensitivity of 500 copies/ml. - (twice as sensitive as the assay Agouron used in their FDA filing). Work will also examine T-20 for use in combination with approved drugs for treatment of HIV. Trimeris also has drug candidates for Respitory Syncytial Virus & Human Parainfluenza Virus.https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=1695338013210